29 completed, 16 recruiting, 14 active not recruiting, 9 not yet recruiting. 22 Phase 1, 13 Phase 2, 11 Phase 3, 8 Not applicable, 5 Phase 4.
Follow Respiratory Syncytial Virus (RSV): new trials by email Literature Review of Respiratory Syncytial Virus (RSV) trials Research Report on Respiratory Syncytial Virus (RSV)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults RSVpreF (Regimen A), RSVpreF (Regimen B) - Respiratory Syncytial Virus (RSV) | Phase 3 | Not yet recruiting | Pfizer | 750 | 2026-10-29 | 2026-10-21 |
| A Phase II Clinical Study to Evaluate the Efficacy and Safety of YKYY018 for Inhalation Solution YKYY018 for Inhalation Solution, YKYY018 Placebo - Respiratory Syncytial Virus (RSV) | Phase 2 | Not yet recruiting | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. | 160 | 2026-10-10 | 2026-09-08 |
| ELderly REspiratory VIral Cohort Respiratory viral infection - Influenza Viruses, Respiratory Syncytial Virus (RSV) | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 1000 | 2026-10-01 | 2026-09-10 | |
| Immunogenicity and Safety of Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients RSVPreF3 vaccination - Vaccination, Respiratory Syncytial Virus (RSV) | Phase 4 | Recruiting | Seoul National University Hospital | 80 | 2026-10-01 | 2026-10-26 |
| Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease RSVpreF, Placebo - Respiratory Syncytial Virus (RSV) | Phase 3 | Not yet recruiting | Pfizer | 920 | 2026-09-28 | 2026-09-24 |
| Safety and Preliminary Immunogenicity of Recombinant RSV Vaccine （CHO Cell） in Adults Aged 18 Years and Older Recombinant RSV Vaccine (CHO Cell), Adjuvant Suspension, Recombinant RSV Vaccine (CHO Cell) with Adjuvant Suspension - Respiratory Syncytial Virus (RSV) | Phase 1 | Not yet recruiting | Yikang Biotech (Suzhou) Co., Ltd. | 128 | 2026-09-15 | 2026-09-08 |
| A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults RSVpreF Vaccine - Respiratory Syncytial Virus (RSV) | Phase 3 | Recruiting | Pfizer | 440 | 2026-08-31 | 2026-10-14 |
| A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults mRNA-1365 (Profile 2), mRNA-1345 (Profile 1), mRNA-1345 (Profile 3) - Respiratory Syncytial Virus (RSV), Human Metapneuomovirus (hMPV) | Phase 1 | Recruiting | ModernaTX, Inc. | 375 | 2026-08-11 | 2026-08-19 |
| A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection YKYY025 group, YKYY025 Placebo group - Respiratory Syncytial Virus (RSV) | Phase 1 | Recruiting | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. | 180 | 2026-07-29 | 2026-09-10 |
| A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus zelicapavir, Placebo - RSV Infection, RSV | Phase 2 | Recruiting | Enanta Pharmaceuticals, Inc | 150 | 2026-07-09 | 2026-07-20 |
| Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic Cosmos Respiratory Syncytial Virus (RSV) | Active not recruiting | Pfizer | 293334 | 2026-06-22 | 2026-08-20 | |
| A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF RSVpreF, Placebo - Respiratory Syncytial Virus (RSV) | Phase 3 | Recruiting | Pfizer | 540 | 2026-06-22 | 2026-09-24 |
| THRIVE - Trial of Passive Humoral RSV Immunity for Value and Effectiveness Nirsevimab (RSV-specific monoclonal antibody) - Respiratory Syncytial Virus (RSV), Respiratory Infection Virus | Phase 4 | Recruiting | Menzies School of Health Research | 1000 | 2026-06-17 | 2026-10-07 |
| A Study to Evaluate the Immune Response Features Following Vaccination With a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells) Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) - Respiratory Syncytial Virus (RSV) | Not applicable | Not yet recruiting | MAXVAX Biotechnology Limited Liability Company | 60 | 2026-06-02 | 2026-06-01 |
| A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease. RSVpreF - Respiratory Syncytial Virus (RSV) | Phase 3 | Completed | Pfizer | 130 | 2026-05-11 | 2026-09-24 |
| TARSILA Real-World Evidence Study respiratory syncytial virus bivalent prefusion F vaccine - Respiratory Syncytial Virus (RSV), Maternal Immunization | Not yet recruiting | Inova Medical | 5000 | 2026-04-30 | 2026-03-03 | |
| Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age H5 Flu Investigational Medical Product (IMP) 1, H5 Flu IMP 2, H5 Flu IMP 3 - Respiratory Syncytial Virus (RSV), Influenza A(H5N1) | Phase 1 | Recruiting | Sanofi | 570 | 2026-04-15 | 2026-05-08 |
| Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women MKK900 60 µg, MKK900 120 µg, ABRYSVO® - Respiratory Syncytial Virus (RSV) | Phase 1 | Not yet recruiting | MAXVAX Biotechnology Limited Liability Company | 120 | 2026-04-01 | 2026-03-25 |
| Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infants SIBP-A16 injection, Nirsevimab, SIBP-A16 buffer solution - Respiratory Syncytial Virus (RSV) | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Institute Of Biological Products | 36 | 2026-01-15 | 2026-01-23 |
| Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective Dengue, Chikungunya | Recruiting | Institut Pasteur du Cambodge | 10000 | 2025-12-18 | 2026-01-22 |
Showing 20 of 77. Sign in to see all of them.
Respiratory Syncytial Virus Infections (7) · COVID-19 (6) · Influenza, Human (5) · Bronchiolitis (4) · Adenoviridae Infections (3) · Communicable Diseases (3) · Infections (3) · Enterovirus Infections (2) · Respiratory Tract Diseases (2) · Respiratory Tract Infections (2) · Whooping Cough (2) · Acute Disease (1) · Arenaviridae Infections (1) · Asthma (1) · Behavior (1)
Infections (21) · Respiratory Tract Diseases (17) · RNA Virus Infections (16) · Virus Diseases (16) · Respiratory Tract Infections (13) · Lung Diseases (11) · Mononegavirales Infections (9) · Paramyxoviridae Infections (8) · Coronaviridae Infections (7) · Nidovirales Infections (7) · Pathological Conditions, Signs and Symptoms (7) · Pneumovirus Infections (7) · Coronavirus Infections (6) · Pathologic Processes (6) · Pneumonia (6)
abrysvo (4) · Adjuvants, Pharmaceutic (3) · Saline Solution (3) · nirsevimab (3) · EDP-938 (2) · Palivizumab (2) · Respiratory Syncytial Virus Vaccines (2) · Blood Specimen Collection (1) · Inosine Monophosphate (1) · PC-786 (1) · Prone Position (1) · Regimen B (1) · Surveys and Questionnaires (1) · Vaccines (1) · arexvy (1)
Pfizer (14) · Novavax (5) · MAXVAX Biotechnology Limited Liability Company (4) · Enanta Pharmaceuticals, Inc (3) · AbbVie (2) · Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. (2) · Evidation Health (2) · MedImmune LLC (2) · Shanghai Institute Of Biological Products (2) · Aga Khan University (1) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · CorEvitas (1) · DiaSorin Molecular LLC (1) · EDAN Instruments Inc. (1)
United States (30) · Australia (8) · China (8) · United Kingdom (8) · South Korea (4) · Canada (3) · Germany (3) · Japan (3) · Spain (3) · Thailand (3) · Argentina (2) · Belgium (2) · France (2) · India (2) · Israel (2)
Craig Curtis, MD (2) · D. Nigel Thomas, Ph.D. (2) · Eric Sheldon, MD (2) · Judith Falloon, MD (2) · Andrew Pollard (1) · Andrey Strugovschikov, MD (1) · Ann Falsey (1) · Christina Chang, M.D (1) · Christine Jones (1) · Claude Flamand, Ph.D. (1)
PMID 26259809, PMID 27102821, PMID 28413427, PMID 28679495, PMID 30401620, PMID 30418358, PMID 30987852, PMID 32702120, PMID 32794560, PMID 33131932, PMID 35291998, PMID 35902389, PMID 36542692, PMID 36964084, PMID 38626982, PMID 39523547, PMID 40266222, PMID 40770421, PMID 41660362, PMID 42015169
2016 (2), 2014 (1), 2015 (1), 2025 (1)